Press Release
Stay updated with our latest news and media
Daewoong Pharmaceutical Indonesia Receives GMP Certification for Stem Cells, NK Cells, and Exosomes… Opening a New Era of High-Quality Cell Therapy
Writer
Manager
September 2, 2025
 - Local production of autologous stem cells, NK cells, and exosomes enables full pipeline manufacturing of cell therapies.
- Proven manufacturing quality and safety of cell therapies accelerate the expansion of an integrated regenerative medicine service in partnership with local affiliates.
- In response to population aging and the rise of intractable diseases, the company collaborates with hospitals to deliver personalized cell therapy solutions for patients.

 

(Jakarta, September 3rd 2025)

Daewoong Pharmaceutical Indonesia announced on the 1st that it had received GMP (Good Manufacturing Practice) certification from Indonesia’s BPOM for its production facilities for autologous stem cells, NK cells, and exosomes.

Following its 2024 GMP certification for allogeneic stem cell facilities, Daewoong Pharmaceutical Indonesia has now expanded local production capabilities to cover the full pipeline of cell-based therapeutics—including autologous stem cells, NK cells, exosomes, and cell culture media. The new GMP certification further validates the safety and quality of Daewoong’s cell therapy manufacturing.

This certification is significant in that it offers new hope for patients who have reached the limits of conventional treatments, providing access to personalized cell therapies and advancing precision medicine. The facility integrates the advanced clinical, research, and production technologies of Daewoong’s Yongin Cell Therapy Center in Korea, supporting the co-growth of Indonesia’s regenerative medicine industry.

Baik In Hyun, Head of the Business Unit mentioned that “In addition to being a business milestone, this GMP certification serves as a testament to the standardization and safety of our cell therapy manufacturing. It enables us to provide safer, more reliable cell therapy services to Indonesian patients, and we will continue expanding our personalized solutions going forward.” He added, “Through close collaboration with local hospitals and healthcare professionals, we are committed to ensuring stable access to high-quality regenerative treatments.”

According to the 2024 Asia-Pacific Population Report, Indonesia’s population is aging, with 7.3% aged 65 and over, and 11.1% aged 60 and over. In response, Daewoong Pharmaceutical Indonesia (DPI) is partnering with hospitals and universities to advance local research in personalized cell therapy while also fostering talent development.

Daewoong Pharmaceutical Indonesia is also working with its local affiliates—Selatox, CGBIO Indonesia, and Nulook Clinic—to expand an integrated regenerative medicine ecosystem. CGBIO Indonesia supplies a variety of aesthetic and regenerative solutions such as fillers, adhesion barriers, and tissue regeneration devices, while providing hands-on training and academic programs to elevate local medical expertise. Located in Bali, Nulook Clinic serves as a hub for stem cell-based anti-aging procedures and K-aesthetic experiences, representing a key example of medical tourism and regenerative medicine convergence in Indonesia.

Since establishing its Jakarta office in 2005, Daewoong has pursued sustainable growth through localization and technology transfer for over 20 years. In 2012, the company built Indonesia’s first biopharmaceutical plant, Daewoong Infion, supplying halal-certified EPO and EGF products. The recent addition of a stem cell production facility further strengthens Indonesia’s regenerative medicine infrastructure. Building on this local experience and global network, Daewoong aims to provide competitive solutions in the global healthcare industry.

recent post
Forward
Press Release
Daewoong Pharmaceutical Indonesia Receives GMP Certification for Stem Cells, NK Cells, and Exosomes… Opening a New Era of High-Quality Cell Therapy
Press Release
Daewoong Foundation Announces Call for Applications for the 2025 Young Medical Scientist Research Grant